Healthcare giant Abbott will split into 2 parts starting tomorrow, separating its proprietary drug division from the generics, diagnostics, devices and nutrition arm.

MASSDEVICE ON CALL — Healthcare giant Abbott (NYSE:ABT) will officially split into 2 parts starting tomorrow, essentially separating the proprietary drug division from the rest of the company.

The split, initially announced in October 2011, will spin out the research pharmaceuticals division into a publicly traded firm dubbed AbbVie (NYSE:ABBV), the stock for which hit the market earlier this month.